7 completed, 5 terminated, 2 active not recruiting, 1 withdrawn. 8 Phase 2, 4 Phase 3, 3 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Terminated 4 |
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Steba Biotech S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study padeliporfin VTP - Transitional Cell Cancer of Renal Pelvis and Ureter | Phase 3 | Active not recruiting | Steba Biotech S.A. | 89 | 2021-03-22 | 2026-07-30 |
| Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer TOOKAD® - Localized Prostate Cancer | Phase 3 | Withdrawn | Steba Biotech S.A. | 2020-03-31 | 2020-11-13 | |
| Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer TOOKAD VTP - Low Risk Prostate Cancer | Phase 4 | Terminated | Steba Biotech S.A. | 23 | 2019-01-21 | 2021-03-23 |
| Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. TOOKAD Soluble 4 mg/kg - Localized Prostate Cancer | Phase 2 | Completed | Steba Biotech S.A. | 50 | 2017-10-02 | 2026-09-10 |
| A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing WST 11-mediated VTP therapy - Esophagogastric Cancer, Moderate to Severe Dysphagia | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2017-04-26 | 2026-04-16 |
| European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up no intervention (post study follow up) - Cancer of the Prostate | Completed | Steba Biotech S.A. | 374 | 2016-03-17 | 2021-03-22 | |
| Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer TOOKAD® Soluble - Prostate Cancer | Phase 3 | Completed | Steba Biotech S.A. | 81 | 2013-05-01 | 2016-04-19 |
| Vascular Targeted Photodynamic Therapy T1a Renal Tumours Light activated WST11 - Renal Cancer | Phase 1 / Phase 2 | Terminated | University of Oxford | 5 | 2013-05-01 | 2018-01-10 |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. TOOKAD® Soluble - Prostate Cancer | Phase 3 | Completed | Steba Biotech S.A. | 413 | 2011-02-01 | 2019-07-11 |
| Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD STAKEL - Macular Degeneration, Choroidal Neovascularization | Phase 2 | Terminated | Steba Biotech S.A. | 10 | 2010-06-01 | 2018-09-17 |
| Study Using WST11 in Patients With Localized Prostate Cancer WST11 - Prostate Cancer | Phase 2 | Completed | Steba Biotech S.A. | 86 | 2009-09-01 | 2015-04-28 |
| Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma WST11 - Cholangiocarcinoma | Phase 2 | Terminated | Steba Biotech S.A. | 8 | 2009-09-01 | 2016-04-18 |
| Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer WST11 - Non-Small Cell Lung Cancer | Phase 2 | Terminated | Steba Biotech S.A. | 3 | 2009-09-01 | 2015-04-28 |
| Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer WST 11 -mediated -VTP - Prostate Cancer | Phase 1 / Phase 2 | Completed | Steba Biotech S.A. | 30 | 2009-07-01 | 2024-02-07 |
| Study of WST11 in Patients With Localized Prostate Cancer WST11 - Prostate Cancer | Phase 2 | Completed | Steba Biotech S.A. | 42 | 2008-09-01 | 2016-04-19 |
Carcinoma (7) · Prostatic Neoplasms (7) · Genital Neoplasms, Male (6) · Male Urogenital Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Prostatic Diseases (6) · Urogenital Neoplasms (6) · Genital Diseases, Male (4) · Genital Diseases (2) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Choroidal Neovascularization (1) · Kidney Neoplasms (1) · Lung Neoplasms (1)
padeliporfin (10) · Therapeutics (1) · palladium-bacteriopheophorbide (1)
France (9) · United States (6) · United Kingdom (5) · Germany (3) · Netherlands (3) · Spain (3) · Finland (2) · Israel (2) · Italy (2) · Sweden (2) · Belgium (1) · Canada (1) · Mexico (1) · Panama (1) · Peru (1)
Jonathan Coleman, MD (2) · Mark Emberton, Professor (2) · Adrienne Scott, Doctor (1) · Emmanuel Ben Soussan, MD (1) · Francine Behar Cohen, Professor (1) · Hans Gerdes, MD (1) · John Wells, Professor (1) · Jose Arturo Rodriguez Rivera, Dr (1) · Luis Zegarra Montes, Professor (1) · Mark Sullivan, MD FRCS Urol (1)
PMID 25712310, PMID 25614256, PMID 25786708, PMID 21296274, PMID 24028764, PMID 24841929, PMID 27291652, PMID 28007457
2018 (1)